



NDA 017963/S-074

SUPPLEMENT APPROVAL

Validus Pharmaceuticals LLC
Attention: Jessica Oliveros
Manager, Regulatory Affairs
90 East Halsey Road, Suite 210
Parsippany, NJ 07054

Dear Ms. Oliveros:

Please refer to your supplemental new drug application (sNDA) dated May 7, 2018, received May 7, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lopressor (metoprolol tartrate) 50 mg and 100 mg Tablets.

This Prior Approval supplemental new drug application provides for revisions to the prescribing information consistent with the Physician Labeling Rule (PLR), including revisions to comply with the Pregnancy Lactation and Labeling Rule (PLLR), this supplement also provides for revisions to the Warnings and Precautions (5.6) and Patient Counseling Information (17) sections to include updated language regarding hypoglycemia. In addition to editorial and organization revisions throughout labeling, content revisions have been made to the following sections, Indications and Usage, Dosage and Administration, Warnings and Precautions, Drug Interactions, Use in Specific Populations, Description and Clinical Pharmacology.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

If you have any questions, please call Maryam Changi, Regulatory Project Manager, at (240) 402-2725.

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, PharmD
Deputy Director for Safety
Division of Cardiology and Nephrology
Office of Cardiology, Hematology, Endocrinology,
and Nephrology
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

MARY R SOUTHWORTH
07/05/2023 05:16:06 PM